Abstract
Recently, the study of microRNAs has expanded our knowledge of the fundamental processes of cancer biology and the underlying mechanisms behind tumor metastasis. Extensive research in the fields of microRNA and its novel mechanisms of actions against various cancers has more recently led to the trial of a first cancer-targeted microRNA drug, MRX34. Yet, these microRNAs are mostly being studied and clinically trialed solely based on the understanding of their cell biologic effects, thus, neglecting the important immunologic effects that are sometimes opposite of the cell biologic effects. Here, we summarize both the cell biologic and immunologic effects of various microRNAs and discuss the importance of considering both effects before using them in clinical settings. We stress the importance of understanding the miRNA's effect on cancer metastasis from a “systems” perspective before developing a miRNA-targeted therapeutic in treating cancer metastasis.
Original language | English |
---|---|
Article number | e1230579 |
Journal | OncoImmunology |
Volume | 5 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2016 Nov 1 |
Bibliographical note
Publisher Copyright:© 2016 Taylor & Francis Group, LLC.
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Oncology